Completed PHASE3 INTERVENTIONAL 3-arm NCT01471730

The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery (ZEPLAST)

The ZEroPLASmaTrial (ZEPLAST): a Randomized, Controlled Trial on Transfusion Avoidance in High Transfusion-risk Cardiac Surgery Patients

Sponsor: CSL Behring

Conditions Heart Disease

Interventions Fibrinogen Prothrombin complex Saline solution

Updated 5 times since 2017 Last updated: Mar 29, 2015 Started: Nov 30, 2011 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01471730, this PHASE3 trial focuses on Heart Disease and remains completed. Sponsored by CSL Behring, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring
IRCCS Policlinico S. Donato

Data source: IRCCS Policlinico S. Donato

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Donato Milanese, Italy